Buscar

The program becomes first of its kind to be accredited in Nevada Renown Health is pleased to announce the certification of the Thomas S. Dolan Pulmonary Rehabilitation program at Renown South Meadows Medical Center by the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR). AACVPR certification demonstrates that an organization's Pulmonary Rehabilitation Program is aligned with current guidelines set by the American Association of Cardiovascular and Pulmonary Rehabilitation for appropriate and effective early outpatient care of patients with cardiac or pulmonary issues. Certification offers peace of mind, so that patients can feel confident in knowing that staff has the experience and skills necessary to coordinate the many issues faced by people receiving a life-changing cardiac or pulmonary diagnosis.  Pulmonary rehabilitation programs help people with health issues such as asthma, chronic bronchitis, pulmonary fibrosis, or chronic obstructive pulmonary disease (COPD) recover faster and live healthier.  “Having access to quality pulmonary rehabilitation services so close to home, staffed by a highly skilled group of compassionate care providers, truly is a gift to our community,” said Tony Slonim,MD, D.Ph., president and CEO of Renown. “We are extremely proud of the work being done in our pulmonary rehabilitation program, and also forever grateful for Tom Dolan’s donation to the program in 2019, which empowers Nevadans to improve both their health and quality of life.”  “Thomas S. Dolan Pulmonary Rehabilitation is the only accredited pulmonary rehabilitation program in the state of Nevada,” said Renown South Meadows Medical Center and Rehabilitation Hospital Vice President Chris Nicholas. “We take pride in this distinguished honor from the AACVPR as it acknowledges and amplifies the life-changing work happening here. Our dedicated caregivers provide support to our patients every step of the way, helping them lead vibrant and fulfilling lives despite their health conditions.” The comprehensive pulmonary rehabilitation program at Renown South Meadows Medical Center offers treadmills, stationary bicycles, strength training and an education classroom to help patients achieve health goals. To earn accreditation, Renown’s pulmonary rehabilitation program participated in an application process requiring extensive documentation of the program’s practices. AACVPR Program Certification is the only peer-review accreditation process designed to review individual programs for adherence to standards and guidelines developed and published by AACVPR and other related professional societies. In November 2019, Tom Dolan, owner and founder of Dolan Auto Group, donated to the Pulmonary Rehabilitation at Renown South Meadows Medical Center after his personal experience thriving in pulmonary rehabilitation brought northern Nevada’s capabilities, and needs to his attention. His generous donation has allowed Renown to double the number of patients who receive treatment and increase the access to pulmonary rehab in our community. “As a former patient myself, I found so much benefit in my pulmonary rehab,” said Dolan. “I have always wanted to support this program and increase the number of people it serves. It’s great to see that we now have the only certified pulmonary rehab in Nevada. “The most essential component of lung health is breaking the cycle of inactivity associated with lung disease,” said Lung Critical Care Physician Dr. Farah Madhani-Lovely. “Our community is fortunate to have an accredited program like this to empower our patients.”   About AACVPR Founded in 1985, the American Association of Cardiovascular and Pulmonary Rehabilitation is a multidisciplinary organization dedicated to the mission of reducing morbidity, mortality and disability from cardiovascular and pulmonary disease through education, prevention, rehabilitation, research and disease management. Central to the core mission is improving the quality of life for patients and their families. Learn more about AACVPR at www.aacvpr.org.

Read More About Thomas S Dolan Pulmonary Rehabilitation Program

Breast cancer screening has long been a cornerstone of women's healthcare. With 1 in 8 women diagnosed with breast cancer in their lifetime1, the United States Preventive Services Task Force (USPSTF) has developed screening recommendations to help detect early-stage cancer. Notably in 2023, the USPSTF revised the recommended age for biennial mammogram screenings for women with average risk to start at age 40 instead of 502, estimated to result in 19% more lives being saved3 by starting screening earlier. While initiating screening at an earlier age offers advantages to a wide demographic, concerns about the potential of over-screening prompted research into the feasibility of identifying women with lower breast cancer risk who could safely delay mammograms. While guidelines address high-risk individuals, a notable gap exists in providing recommendations tailored to those at lower risk. To gain insight into a patient's risk level, physicians are able to utilize genetic testing to understand an individual's genetic makeup, providing precise insights into their predisposition to various health conditions, including breast cancer. Armed with this genetic information, healthcare providers could craft tailored screening strategies that align with an individual’s specific risk profile. This genetic risk-based approach underscores the value of genetics in individualizing the onset of screening to help avoid over-screening and its associated costs. Surprisingly, genetic information is not currently being widely utilized to identify women at risk of breast cancer or other diseases in clinical practice, despite its potential to make a significant positive impact for patients. A recent retrospective analysis of 25,591 women from the Healthy Nevada Project4 sheds light on the potential benefits of this genetic risk-based approach. The study classified 2,338 (9.1%) of these women as having a low genetic risk for breast cancer. What's remarkable is that these women exhibited a significantly lower and later onset of breast cancer compared to their average or high-risk counterparts. This finding suggests that it might be safe for low-risk women to delay mammogram screening by 5 to 10 years without compromising their health.

Read More About Optimizing Mammogram Screenings: A Genetic Approach to a Personalized Screening Schedule